Stockreport

Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium

Exact Sciences Corporation  (EXAS) 
Last exact sciences corporation earnings: 2/11 04:05 pm Check Earnings Report
PDF First clinical validation of the Oncodetect ® test to be presented in triple negative breast cancer; signals highly sensitive molecular residual disease (MRD) detectionT [Read more]